Princeton Capital Management LLC Purchases 133 Shares of Zoetis Inc. (NYSE:ZTS)

Princeton Capital Management LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 1.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,488 shares of the company’s stock after purchasing an additional 133 shares during the period. Zoetis comprises approximately 0.7% of Princeton Capital Management LLC’s holdings, making the stock its 28th biggest position. Princeton Capital Management LLC’s holdings in Zoetis were worth $2,244,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Caprock Group LLC raised its stake in shares of Zoetis by 7.3% in the third quarter. Caprock Group LLC now owns 11,984 shares of the company’s stock worth $2,342,000 after buying an additional 811 shares during the period. Pathstone Holdings LLC increased its holdings in Zoetis by 0.5% in the 3rd quarter. Pathstone Holdings LLC now owns 60,660 shares of the company’s stock worth $11,852,000 after acquiring an additional 310 shares in the last quarter. Quest Partners LLC raised its stake in Zoetis by 328.8% during the 3rd quarter. Quest Partners LLC now owns 10,407 shares of the company’s stock worth $2,033,000 after acquiring an additional 7,980 shares during the period. Alpha Family Trust purchased a new position in Zoetis during the third quarter valued at approximately $213,000. Finally, Turtle Creek Wealth Advisors LLC boosted its position in shares of Zoetis by 2.2% in the third quarter. Turtle Creek Wealth Advisors LLC now owns 30,521 shares of the company’s stock worth $5,963,000 after purchasing an additional 664 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.7 %

Shares of Zoetis stock opened at $176.42 on Tuesday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The firm’s 50 day simple moving average is $186.78 and its two-hundred day simple moving average is $180.45. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $79.60 billion, a price-to-earnings ratio of 33.16, a PEG ratio of 2.69 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.36 EPS. Analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ZTS. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Piper Sandler boosted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.